Just as a disciplined a soccer player might pass on a hopeful shot in favor of a better chance later on, the biopharma venture capital market reflected a preference for de-risked assts over platforms ...

A new report out today from PitchBook Data Inc. offers a cautiously optimistic outlook for U.S. venture capital-backed initial public offerings in 2026, arguing that although the IPO window has ...

Morningstar has launched an index tracking late-stage pure-play GenAI companies as they transition from private to public markets. Called Morningstar PitchBook GenAI 20, the index tracks the 20 ...

SEATTLE--(BUSINESS WIRE)--Morningstar (Nasdaq: MORN), a leading provider of independent investment insights, today announced that Rod Diefendorf will be appointed the next leader of PitchBook as ...

The global venture capital market hit its second-highest annual total on record in 2025, with the year seeing $512 billion in deal value, nearly matching 2022, the current high-water mark, according ...

Morningstar and PitchBook’s Model Context Protocol (MCP) app integrations are now live, enabling licensed users to access proprietary public and private market data and insights securely within ...

SEATTLE--(BUSINESS WIRE)--PitchBook, the leading private capital market intelligence provider, has released its 2026 Outlook report series, offering a data-driven view of the investment trends ...

A new report out today from private capital market intelligence company PitchBook Data Inc. paints a picture of artificial intelligence as the defining infrastructure layer for the next half-century, ...

* Half of respondents to a PitchBook survey said theirprimary area of focus was exiting portfolio companies, while 8%said they anticipate holding off until market conditions becomeclearer. * The ...

NEW YORK, Dec 4 (Reuters) - Private equity firms in the United States are on track to cash out more of their investments this year than in 2024 in a welcome recovery for dealmaking, but transactions ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. The medtech industry is approaching 2026 in an improving ...

Artificial intelligence is booming across biopharma, with deployed tech taking aim at the industry’s biggest challenges: the significant risk of failure, high costs and long development timelines. And ...